Experimental Alzheimer’s Pill Boosts the Brain’s Cleanup System

It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...

Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...

Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...